4.6 Review

Can oncology recapitulate paleontology? Lessons from species extinctions

Journal

NATURE REVIEWS CLINICAL ONCOLOGY
Volume 12, Issue 5, Pages 273-285

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2015.12

Keywords

-

Categories

Funding

  1. National Institute for Health Research Academic Clinical Fellowship
  2. Cancer Research UK
  3. Rosetrees Trust
  4. Breast Cancer Research Foundation
  5. Prostate Cancer Foundation
  6. European Union
  7. European Research Council
  8. National Science Foundation [DEB-1021243]
  9. NIH [R01-AI091646, P01 CA91955, R01 CA149566, R01 CA170595, R01 CA140657]
  10. American Cancer Society [117209-RSG-09-163-01-CNE]
  11. CDMRP Breast Cancer Research Program Award [BC132057]
  12. Cancer Research UK [19310, 17786] Funding Source: researchfish
  13. National Institute for Health Research [ACF-2012-22-001] Funding Source: researchfish
  14. Rosetrees Trust [M179] Funding Source: researchfish
  15. The Francis Crick Institute [10169, 10174, 10303, 10172, 10359, 10170] Funding Source: researchfish

Ask authors/readers for more resources

Although we can treat cancers with cytotoxic chemotherapies, target them with molecules that inhibit oncogenic drivers, and induce substantial cell death with radiation, local and metastatic tumours recur, resulting in extensive morbidity and mortality. Indeed, driving a tumour to extinction is difficult. Geographically dispersed species of organisms are perhaps equally resistant to extinction, but >99.9% of species that have ever existed on this planet have become extinct. By contrast, we are nowhere near that level of success in cancer therapy. The phenomena are broadly analogous-in both cases, a genetically diverse population mutates and evolves through natural selection. The goal of cancer therapy is to cause cancer cell population extinction, or at least to limit any further increase in population size, to prevent the tumour burden from overwhelming the patient. However, despite available treatments, complete responses are rare, and partial responses are limited in duration. Many patients eventually relapse with tumours that evolve from cells that survive therapy. Similarly, species are remarkably resilient to environmental change. Paleontology can show us the conditions that lead to extinction and the characteristics of species that make them resistant to extinction. These lessons could be translated to improve cancer therapy and prognosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Impact of cancer evolution on immune surveillance and checkpoint inhibitor response

Yin Wu, Dhruva Biswas, Charles Swanton

Summary: Intratumour heterogeneity (ITH) can affect the response of patients to immune checkpoint inhibitor (CPI) therapy, confounding the accuracy of predictive biomarkers and playing a role in both immune surveillance and immune evasion. A deeper understanding of the interaction between ITH and the immune system can potentially increase the proportion of patients experiencing durable responses from CPI therapy.

SEMINARS IN CANCER BIOLOGY (2022)

Article Multidisciplinary Sciences

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

Min Zhang, Jin-Li Luo, Qianqian Sun, James Harber, Alan G. Dawson, Apostolos Nakas, Sara Busacca, Annabel J. Sharkey, David Waller, Michael T. Sheaff, Cathy Richards, Peter Wells-Jordan, Aarti Gaba, Charlotte Poile, Essa Y. Baitei, Aleksandra Bzura, Joanna Dzialo, Maymun Jama, John Le Quesne, Amrita Bajaj, Luke Martison, Jacqui A. Shaw, Catrin Pritchard, Tamihiro Kamata, Nathaniel Kuse, Lee Brannan, Pan De Philip Zhang, Hongji Yang, Gareth Griffiths, Gareth Wilson, Charles Swanton, Frank Dudbridge, Edward J. Hollox

Summary: This study analyzed the impact of evolution on the survival and immune landscape of patients with malignant pleural mesothelioma (MPM) using multi-region sequencing data, revealing the significant influence of clonal architecture and evolutionary clusters on disease inflammation and immune evasion.

NATURE COMMUNICATIONS (2021)

Review Oncology

Tracking Cancer Evolution through the Disease Course

Chris Bailey, James R. M. Black, James L. Reading, Kevin Litchfield, Samra Turajlic, Nicholas McGranahan, Mariam Jamal-Hanjani, Charles Swanton

Summary: TRACERx studies focus on tracking cancer evolution in a clinical setting, from primary disease to recurrence. Through multiregion and longitudinal sampling, TRACERx has detailed the evolutionary processes in tumor and immune microenvironment in non-small cell lung cancer and clear-cell renal cell carcinoma, revealing the therapeutic potential of targeting clonal neoantigens and ctDNA detection in the adjuvant setting.

CANCER DISCOVERY (2021)

Article Oncology

Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

Subramanian Venkatesan, Mihaela Angelova, Clare Puttick, Haoran Zhai, Deborah R. Caswell, Wei-Ting Lu, Michelle Dietzen, Panagiotis Galanos, Konstantinos Evangelou, Roberto Bellelli, Emilia L. Lim, Thomas B. K. Watkins, Andrew Rowan, Vitor H. Teixeira, Yue Zhao, Haiquan Chen, Bryan Ngo, Lykourgos-Panagiotis Zalmas, Maise Al Bakir, Sebastijan Hobor, Eva Gronroos, Adam Pennycuick, Ersilia Nigro, Brittany B. Campbell, William L. Brown, Ayse U. Akarca, Teresa Marafioti, Mary Y. Wu, Michael Howell, Simon J. Boulton, Cosetta Bertoli, Tim R. Fenton, Robertus A. M. de Bruin, Apolinar Maya-Mendoza, Eric Santoni-Rugiu, Robert E. Hynds, Vassilis G. Gorgoulis, Mariam Jamal-Hanjani, Nicholas McGranahan, Reuben S. Harris, Sam M. Janes, Jirina Bartkova, Samuel F. Bakhoum, Jiri Bartek, Nnennaya Kanu, Charles Swanton

Summary: The study reveals that APOBEC3 genes are upregulated in breast and lung preinvasive lesions, and APOBEC3B exacerbates DNA replication stress to promote cellular diversity and chromosomal instability for early selection in cancer evolution.

CANCER DISCOVERY (2021)

Article Ecology

Selection of metastasis competent subclones in the tumour interior

Yue Zhao, Xiao Fu, Jose I. Lopez, Andrew Rowan, Lewis Au, Annika Fendler, Steve Hazell, Hang Xu, Stuart Horswell, Scott T. C. Shepherd, Lavinia Spain, Fiona Byrne, Gordon Stamp, Tim O'Brien, David Nicol, Marcellus Augustine, Ashish Chandra, Sarah Rudman, Antonia Toncheva, Lisa Pickering, Erik Sahai, James Larkin, Paul A. Bates, Charles Swanton, Samra Turajlic, Ben Challacombe, Simon Chowdhury, William Drake, Archana Fernando, Nicos Fotiadis, Andrew Furness, Emine Hatipoglu, Karen Harrison-Phipps, Peter Hill, Catherine Horsfield, Teresa Marafioti, Jonathon Olsburgh, Alexander Polson, Sergio Quezada, Mary Varia, Hema Verma, Kevin Litchfield

Summary: The study combines whole-tumour images and genomic data to reveal more aggressive subclonal growth and metastasizing subclones in the tumor center. Spatial dynamics strongly correlate with genomic alterations and play a significant role in tumor evolution.

NATURE ECOLOGY & EVOLUTION (2021)

Article Oncology

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

E. A. Klein, D. Richards, A. Cohn, M. Tummala, R. Lapham, D. Cosgrove, G. Chung, J. Clement, J. Gao, N. Hunkapiller, A. Jamshidi, K. N. Kurtzman, M. Seiden, C. Swanton, M. C. Liu

Summary: This study confirmed the feasibility of using the refined MCED test version as a screening tool, demonstrating high specificity and accuracy in predicting CSO, and detecting signals of various cancers.

ANNALS OF ONCOLOGY (2021)

Article Multidisciplinary Sciences

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lu, Kyaw Thein, Benjamin S. Simpson, Jianfeng Chen, Ryan Sun, Omar Alhalabi, Ruiping Wang, Minghao Dang, Enyu Dai, Shaojun Zhang, Fengqi Nie, Shuangtao Zhao, Charles Guo, Ameer Hamza, Bogdan Czerniak, Chao Cheng, Arlene Siefker-Radtke, Krishna Bhat, Andrew Futreal, Guang Peng, Jennifer Wargo, Weiyi Peng, Humam Kadara, Jaffer Ajani, Charles Swanton, Kevin Litchfield, Jordi Rodon Ahnert, Jianjun Gao, Linghua Wang

Summary: This study found that the loss of 9p21.3 leads to a cold tumor immune phenotype, reducing the responsiveness of tumors to immune checkpoint therapy and resulting in worse outcomes. By incorporating 9p21 loss, PD-L1 expression, and TMB levels in pre-treatment tumors, a response score was derived that can accurately identify patients likely to achieve sustained response to therapy.

NATURE COMMUNICATIONS (2021)

Article Biology

Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

Nikhil Faulkner, Kevin W. Ng, Mary Y. Wu, Ruth Harvey, Marios Margaritis, Stavroula Paraskevopoulou, Catherine Houlihan, Saira Hussain, Maria Greco, William Bolland, Scott Warchal, Judith Heaney, Hannah Rickman, Moria Spyer, Daniel Frampton, Matthew Byott, Tulio de Oliveira, Alex Sigal, Svend Kjaer, Charles Swanton, Sonia Gandhi, Rupert Beale, Steve J. Gamblin, John W. McCauley, Rodney Stuart Daniels, Michael Howell, David Bauer, Eleni Nastouli, George Kassiotis

Summary: The study found that antibodies elicited by infection with the B.1.1.7 variant exhibited significantly reduced recognition and neutralization of parental strains or the South Africa variant B.1.351, indicating an asymmetric heterotypic immunity induced by SARS-CoV-2 variants.

ELIFE (2021)

Review Oncology

A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer

G. Middleton, H. Robbins, F. Andre, C. Swanton

Summary: Based on the results from several platform studies, it has been concluded that genotype-matched therapy is effective for cancer patients, but there are still challenges in combination therapy. Precision medicine holds great promise in cancer treatment, but more accurate models are needed to capture the genomic complexity of human diseases.

ANNALS OF ONCOLOGY (2022)

Article Oncology

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

Lewis Au, Emine Hatipoglu, Marc Robert de Massy, Kevin Litchfield, Gordon Beattie, Andrew Rowan, Desiree Schnidrig, Rachael Thompson, Fiona Byrne, Stuart Horswell, Nicos Fotiadis, Steve Hazell, David Nicol, Scott T. C. Shepherd, Annika Fendler, Robert Mason, Lyra Del Rosario, Kim Edmonds, Karla Lingard, Sarah Sarker, Mary Mangwende, Eleanor Carlyle, Jan Attig, Kroopa Joshi, Imran Uddin, Pablo D. Becker, Mariana Werner Sunderland, Ayse Akarca, Ignazio Puccio, William W. Yang, Tom Lund, Kim Dhillon, Marcos Duran Vasquez, Ehsan Ghorani, Hang Xu, Charlotte Spencer, Jose Lopez, Anna Green, Ula Mahadeva, Elaine Borg, Miriam Mitchison, David A. Moore, Ian Proctor, Mary Falzon, Lisa Pickering, Andrew J. S. Furness, James L. Reading, Roberto Salgado, Teresa Marafioti, Mariam Jamal-Hanjani, George Kassiotis, Benny Chain, James Larkin, Charles Swanton, Sergio A. Quezada, Samra Turajlic

Summary: The ADAPTeR study aimed to investigate the mechanism of therapeutic response to nivolumab in metastatic clear cell renal cell carcinoma, with genomic analysis showing no correlation between tumor molecular features and response. Pre-existing immunity may play a key role in predicting clinical response.

CANCER CELL (2021)

Letter Oncology

Immune responses following third COVID-19 vaccination are reduced in patients with hematological compared to patients with solid cancer

Annika Fendler, Scott T. C. Shepherd, Lewis Au, Katalin A. Wilkinson, Mary Wu, Andreas M. Schmitt, Zayd Tippu, Sheima Farag, Aljosja Rogiers, Ruth Harvey, Eleanor Carlyle, Kim Edmonds, Lyra Del Rosario, Karla Lingard, Mary Mangwende, Lucy Holt, Hamid Ahmod, Justine Korteweg, Tara Foley, Taja Barber, Andrea Emslie-Henry, Niamh Caulfield-Lynch, Fiona Byrne, Benjamin Shum, Camille L. Gerard, Daqi Deng, Svend Kjaer, Ok-Ryul Song, Christophe Queval, Caitlin Kavanagh, Emma C. Wall, Edward J. Carr, Sina Namjou, Simon Caidan, Mike Gavrielides, James I. MacRae, Gavin Kelly, Kema Peat, Denise Kelly, Aida Murra, Kayleigh Kelly, Molly O'Flaherty, Robyn L. Shea, Gail Gardner, Darren Murray, Nadia Yousaf, Shaman Jhanji, Nicholas Van As, Kate Young, Andrew J. S. Furness, Lisa Pickering, Rupert Beale, Charles Swanton, Sonia Gandhi, Steve Gamblin, David L. V. Bauer, George Kassiotis, Michael Howell, Emma Nicholson, Susanna Walker, Robert J. Wilkinson, James Larkin, Samra Turajic

CANCER CELL (2022)

Article Gastroenterology & Hepatology

Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts

Michele Bortolomeazzi, Mohamed Reda Keddar, Lucia Montorsi, Amelia Acha-Sagredo, Lorena Benedetti, Damjan Temelkovski, Subin Choi, Nedyalko Petrov, Katrina Todd, Patty Wai, Johannes Kohl, Tamara Denner, Emma Nye, Robert Goldstone, Sophia Ward, A. Gareth Wilson, Maise Al Bakir, Charles Swanton, Susan John, James Miles, Banafshe Larijani, Victoria Kunene, Elisa Fontana, Hendrik-Tobias Arkenau, J. Peter Parker, Manuel Rodriguez-Justo, Kai-Keen Shiu, Jo Spencer, D. Francesca Ciccarelli

Summary: This study conducted a comprehensive analysis of the cellular and molecular determinants of response to anti-PD1 immunotherapy in colorectal cancer patients. The findings revealed that response to immunotherapy was associated with factors such as high clonality of immunogenic mutations and clonally expanded T cells, rather than tumor mutational burden (TMB). Additionally, a population of antigen-presenting macrophages interacting with CD8 T cells consistently segregated with response to anti-PD1 agents.

GASTROENTEROLOGY (2021)

Article Ecology

Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study

Xiao Fu, Yue Zhao, Jose I. Lopez, Andrew Rowan, Lewis Au, Annika Fendler, Steve Hazell, Hang Xu, Stuart Horswell, Scott T. C. Shepherd, Charlotte E. Spencer, Lavinia Spain, Fiona Byrne, Gordon Stamp, Tim O'Brien, David Nicol, Marcellus Augustine, Ashish Chandra, Sarah Rudman, Antonia Toncheva, Andrew J. S. Furness, Lisa Pickering, Santosh Kumar, Dow-Mu Koh, Christina Messiou, Derfel ap Dafydd, Matthew R. Orton, Simon J. Doran, James Larkin, Charles Swanton, Erik Sahai, Kevin Litchfield, Samra Turajlic, Paul A. Bates

Summary: The study examined spatial and temporal features of clonal diversification in clear cell renal cell carcinoma using a combined modelling and real tumour analysis approach, providing insights into predicting tumour evolution patterns and subclone diversification levels.

NATURE ECOLOGY & EVOLUTION (2022)

Article Oncology

APOBEC3 as a driver of genetic intratumor heterogeneity

Subramanian Venkatesan, Mihaela Angelova, Jirina Bartkova, Samuel F. Bakhoum, Jiri Bartek, Nnennaya Kanu, Charles Swanton

Summary: Our recent study found that APOBEC3B is upregulated in the preinvasive stages of non-small cell lung cancer and breast cancer. We suggest that APOBEC3 promotes copy number intratumor heterogeneity prior to invasion, thereby providing a substrate for cancer evolution.

MOLECULAR & CELLULAR ONCOLOGY (2023)

No Data Available